Pharmaceuticals
10 pharma executives
These ten pharma executives currently hold C-suite, executive vice president or president roles at pharmaceutical companies, and their careers include chief executive, finance, R&D and manufacturing leadership. Their experience shows how decisions about pipelines, commercial strategy and operations are made at the top of a pharmaceutical company.
Professionals to explore
01—10Albert Bourla
LinkedInExperience: Chief Executive Officer · Pfizer
Chief Executive Officer of Pfizer since 2019 and Chairman of the Board since 2020. Former Chief Operating Officer (2018) and Group President, Pfizer Innovative Health (2014–2017) at Pfizer. His profile notes that he joined Pfizer in 1993 and has held several executive roles across the company.
Daniel Skovronsky
LinkedInExperience: Executive Vice President and Chief Scientific and Product Officer · Eli Lilly and Company
Executive Vice President and Chief Scientific and Product Officer at Eli Lilly and Company since 2025, and former Executive Vice President and Chief Scientific Officer (2018–2025) there. His profile says he leads teams that turn scientific ideas into medicines, serves as president of Lilly Research Laboratories and oversees Lilly's global business development efforts. Former Founder and Chief Executive Officer of Avid Radiopharmaceuticals, Inc. (2005–2012).
Eric A. Hughes, MD, PhD
LinkedInExperience: Executive Vice President Global R&D and Chief Medical Officer · Teva Pharmaceuticals
Executive Vice President Global R&D and Chief Medical Officer at Teva Pharmaceuticals since 2022; his profile says he leads an organization of about 4,000 professionals and oversees development of generic, biosimilar and innovative medicines. Former Senior Vice President, Clinical Development and Translational Medicine at Vertex Pharmaceuticals (2021–2022) and Global Head, Clinical Development and Analytics at Novartis (2020–2021).
Joseph Morrissey
LinkedInExperience: Chief Executive Officer · Organon
Chief Executive Officer of Organon since 2026, after serving there as Interim Chief Executive Officer (2025–2026) and Executive Vice President, Head of Manufacturing and Supply (2021–2025). Former Senior Vice President, Global Animal Health Manufacturing Operations at Merck (2017–2020). His profile says he leads more than 10,000 colleagues who deliver medicines around the world.
Ken Keller
LinkedInExperience: Chairman of the Board, President and CEO and Head of the Global Oncology Business Unit · Daiichi Sankyo
Chairman of the Board, President and CEO and Head of the Global Oncology Business Unit at Daiichi Sankyo since 2014; his profile describes the role as President & CEO of Daiichi Sankyo, Inc. and Global Head of the Daiichi Sankyo Oncology Business. Former President and CEO of American Regent, Inc. (2016–2021) and Executive Vice President and Chief Operating Officer at Spectrum Pharmaceuticals, Inc. (2012–2014).
Luke Miels
LinkedInExperience: Chief Executive Officer · GSK
Chief Executive Officer of GSK since 2026, after serving as CEO Designate (2025) and Chief Commercial Officer (2017–2025) at GSK. Former Regional Head Asia Pacific (2009–2014) and VP Head Metabolism & Anemia Global Marketing (2006–2009) at Roche. His profile lists GSK as a pharmaceutical manufacturing company.
Nelson Ambrogio
LinkedInExperience: President Bayer U.S. Pharmaceuticals · Bayer
President Bayer U.S. Pharmaceuticals since 2026. At Bayer he was also President of Radiology (2024–2026), SVP, General Manager Oncology US (2021–2024), Senior Vice President & General Manager, Women's Healthcare US (2019–2021) and General Manager Australia New Zealand (2015–2019).
Renee Gala
LinkedInExperience: President and Chief Executive Officer · Jazz Pharmaceuticals
President and Chief Executive Officer of Jazz Pharmaceuticals since 2025. Former President and Chief Operating Officer (2023–2025) and EVP and Chief Financial Officer (2020–2023) at Jazz Pharmaceuticals, and a Board Member at Dexcom since 2025. Her profile says she leads a company focused on innovating to transform the lives of patients and their families.
Rob Davis
LinkedInExperience: Chairman and Chief Executive Officer · Merck
Chairman and Chief Executive Officer of Merck since 2022, after serving as Chief Executive Officer and President (2021–2022). Former Executive Vice President, Global Services and Chief Financial Officer (2016–2021) and Executive Vice President and Chief Financial Officer (2014–2016) at Merck, which his profile notes is known as MSD outside the United States and Canada.
Vas Narasimhan
LinkedInExperience: Chief Executive Officer · Novartis
Chief Executive Officer of Novartis since 2018. Former Global Head of Drug Development and Chief Medical Officer (2016–2018) and Global Head, Development (2014–2016) at Novartis. His profile describes him as a physician who briefly worked at McKinsey before joining Novartis in 2005.
Choose the right perspective
Match the executive's function to your question, since a chief executive, a head of R&D and a head of manufacturing see the same business from very different angles. Consider whether their experience is in large global groups or focused specialty companies, and how recently they held the role that matches your decision.
Questions to take into the conversation
- 01How do you decide which pipeline programs to advance, partner or stop?
- 02What changes when a pharmaceutical company moves from development into commercial launch?
- 03How do you weigh manufacturing and supply risk when planning a new product or market?
Reaching pharma executives
How can I contact one of these pharma executives?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 10 companies, including Pfizer, Eli Lilly and Company and Teva Pharmaceuticals, based on profile data retrieved on September 29, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach pharma executives?
You choose the offer, starting at $5 per person. It includes Instant Expert's 20% fee, so an offer that pays the person $100 costs you $125. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot and may describe past or present roles. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal